Exact Mass: 419.339926

Exact Mass Matches: 419.339926

Found 69 metabolites which its exact mass value is equals to given mass value 419.339926, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

N-Palmitoyl tyrosine

(2S)-2-[(1-hydroxyhexadecylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

C25H41NO4 (419.30354260000007)


N-palmitoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Palmitic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Palmitoyl tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Palmitoyl tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Stearidonyl carnitine

3-[(4Z,8Z,12Z,15Z)-octadeca-4,8,12,15-tetraenoyloxy]-4-(trimethylazaniumyl)butanoate

C25H41NO4 (419.30354260000007)


Stearidonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Stearidonyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoylcarnitine

3-(octadeca-6,9,12,15-tetraenoyloxy)-4-(trimethylazaniumyl)butanoate

C25H41NO4 (419.30354260000007)


(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Oleoyl Histidine

2-[(1-Hydroxyoctadec-9-en-1-ylidene)amino]-3-(1H-imidazol-5-yl)propanoate

C24H41N3O3 (419.3147756000001)


N-oleoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Sarar

N1-[(4-aminophenyl)methyl]-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1,8-diamine

C21H41N9 (419.34847460000003)


   
   
   
   

Octadecanamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-

Octadecanamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-

C26H45NO3 (419.339926)


   

Methyl 3-heneicosyl-1H-pyrrole-2-carboxylate-Methyl 3-alkylpyrrole-2-carboxylates

Methyl 3-heneicosyl-1H-pyrrole-2-carboxylate-Methyl 3-alkylpyrrole-2-carboxylates

C27H49NO2 (419.3763094)


   

(±)N-(2-fluro-ethyl)-2,16,16-trimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine

(±)N-(2-fluro-ethyl)-2,16,16-trimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine

C27H46FNO (419.3563238)


   

(±)N-(2-fluro-ethyl)-2,17,17-trimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine

(±)N-(2-fluro-ethyl)-2,17,17-trimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine

C27H46FNO (419.3563238)


   

(5E,7E)-(3S,24R)-[6,19,19-trideuterio-]-9,10-seco-5,7,10(19)-cholestatriene-3,24,25-triol

(5E)-(24R)-24,25-dihydroxy-[6,19,19-trideutrio]vitamin D3 / (5E)-(24R)-24,25-dihydroxy-[6,19,19-trideutrio]cholecalciferol

C27H41D3O3 (419.347858934)


   
   

(+/-)-2,16,16-trimethyl-5,8,11,14-all-cis-docosatetraenoyl-2-fluoroethyamine

(+/-)N-(2-fluro-ethyl)-2,16,16-trimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine

C27H46FNO (419.3563238)


   

(+/-)N-(2-fluro-ethyl)-2,17,17-trimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine

(+/-)-2,17,17,-trimethyl-5,8,11,14-all-cis-docosatetraenoyl-2-fluoroethylamine

C27H46FNO (419.3563238)


   
   

N-oleoyl histidine

N-(9Z-octadecenoyl)-histidine

C24H41N3O3 (419.3147756000001)


   

ethyl amide-d4

17-phenyl trinor Prostaglandin F2&alpha

C25H33D4NO4 (419.29735291200006)


   

Type IV cyanolipid 22:0 ester

1-docosanoyl-(1-cyano-2-methylprop-2-en-1-ol)

C27H49NO2 (419.3763094)


   

Type III cyanolipid 22:0 ester

Docosanoic acid, 3-cyano-2-methyl-2-propen-1-yl ester

C27H49NO2 (419.3763094)


   

CAR 18:4

3-[(4Z,8Z,12Z,15Z)-octadeca-4,8,12,15-tetraenoyloxy]-4-(trimethylazaniumyl)butanoate

C25H41NO4 (419.30354260000007)


   

(+/-)-2,16,16-trimethyl-5,8,11,14-all-cis-docosatetraenoyl-2-fluoroethyamine

(+/-)N-(2-fluoro-ethyl)-2,16,16-trimethyl-5Z,8Z,11Z,14Z-docosatetraenoyl amine

C27H46NOF (419.3563238)


   

(+/-)-2,17,17,-trimethyl-5,8,11,14-all-cis-docosatetraenoyl-2-fluoroethylamine

(+/-)-2,17,17,-trimethyl-5,8,11,14-all-cis-docosatetraenoyl-2-fluoroethylamine

C27H46NOF (419.3563238)


   

NA 25:5;O3

N-hexadecanoyl-tyrosine

C25H41NO4 (419.30354260000007)


   

NA 26:4;O2

N-[2-(3,4-dihydroxyphenyl)ethyl]-octadecanamide

C26H45NO3 (419.339926)


   

NAT 20:0

N-eicosanoyl taurine

C22H45NO4S (419.30691300000007)


   
   

(1R,3S,5E)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]-1-deuterioethylidene]-4-(dideuteriomethylidene)cyclohexane-1,3-diol

(1R,3S,5E)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]-1-deuterioethylidene]-4-(dideuteriomethylidene)cyclohexane-1,3-diol

C27H41D3O3 (419.347858934)


   

N-(4-Hydroxy-3-methoxybenzyl)octadecanamide

N-(4-Hydroxy-3-methoxybenzyl)octadecanamide

C26H45NO3 (419.339926)


   
   

SNC 162

4-[(S)-[(2S,5R)-2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl]phenylmethyl]-N,N-diethylbenzamide

C27H37N3O (419.2936472)


SNC162 is a delta-opioid receptor agonist with an IC50 of 0.94 nM. SNC162 has antidepressant-like effects and produces a selective enhancement of the antinociceptive effects of fentanyl in rhesus monkeys[1][2].

   

3-[Dimethyl(octadecyl)ammonio]-1-propanesulfonate

3-[Dimethyl(octadecyl)ammonio]-1-propanesulfonate

C23H49NO3S (419.3432964000001)


   

N-Stearoyldopamine

N-Stearoyldopamine

C26H45NO3 (419.339926)


   
   

N-icosanoyltaurine

N-icosanoyltaurine

C22H45NO4S (419.30691300000007)


A fatty acid-taurine conjugate derived from icosanoic acid.

   
   

3-(1H-imidazol-5-yl)-2-[[(E)-octadec-9-enoyl]amino]propanoic acid

3-(1H-imidazol-5-yl)-2-[[(E)-octadec-9-enoyl]amino]propanoic acid

C24H41N3O3 (419.3147756000001)


   

(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoylcarnitine

(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoylcarnitine

C25H41NO4 (419.30354260000007)


   

(9Z,12Z,15Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]octadeca-9,12,15-trienamide

(9Z,12Z,15Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]octadeca-9,12,15-trienamide

C26H45NO3 (419.339926)


   

(6Z,9Z,12Z,15Z)-N-(1,3-dihydroxyoctan-2-yl)octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-(1,3-dihydroxyoctan-2-yl)octadeca-6,9,12,15-tetraenamide

C26H45NO3 (419.339926)


   

(7Z,10Z,13Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]hexadeca-7,10,13-trienamide

C26H45NO3 (419.339926)


   

(4Z,7Z,10Z,13Z)-N-(1,3-dihydroxydecan-2-yl)hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-(1,3-dihydroxydecan-2-yl)hexadeca-4,7,10,13-tetraenamide

C26H45NO3 (419.339926)


   
   

SPHP(22:1)

SPHP(m22:1)

C22H46NO4P (419.31642860000005)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   

NA-Ile 20:3(8Z,11Z,14Z)

NA-Ile 20:3(8Z,11Z,14Z)

C26H45NO3 (419.339926)


   

NA-Leu 20:3(8Z,11Z,14Z)

NA-Leu 20:3(8Z,11Z,14Z)

C26H45NO3 (419.339926)


   
   
   
   

(2s,3r,4as,5s,8ar)-5-[(5r)-5-hydroxyoctyl]-2-methyl-decahydroquinolin-3-yl (2e,4e)-octa-2,4-dienoate

(2s,3r,4as,5s,8ar)-5-[(5r)-5-hydroxyoctyl]-2-methyl-decahydroquinolin-3-yl (2e,4e)-octa-2,4-dienoate

C26H45NO3 (419.339926)


   

methyl 3-henicosyl-1h-pyrrole-2-carboxylate

methyl 3-henicosyl-1h-pyrrole-2-carboxylate

C27H49NO2 (419.3763094)


   

(3r,4z,6e,9z)-n-[(3s,5s)-5-ethyl-5-methyl-2-oxooxolan-3-yl]-3-hydroxyoctadeca-4,6,9-trienimidic acid

(3r,4z,6e,9z)-n-[(3s,5s)-5-ethyl-5-methyl-2-oxooxolan-3-yl]-3-hydroxyoctadeca-4,6,9-trienimidic acid

C25H41NO4 (419.30354260000007)


   

(2z,4z)-22-hydroxy-1-(piperidin-1-yl)docosa-2,4-dien-1-one

(2z,4z)-22-hydroxy-1-(piperidin-1-yl)docosa-2,4-dien-1-one

C27H49NO2 (419.3763094)


   

(2r,3r,4as,5s,8ar)-5-[(5r)-5-hydroxyoctyl]-2-methyl-decahydroquinolin-3-yl (2e,4e)-octa-2,4-dienoate

(2r,3r,4as,5s,8ar)-5-[(5r)-5-hydroxyoctyl]-2-methyl-decahydroquinolin-3-yl (2e,4e)-octa-2,4-dienoate

C26H45NO3 (419.339926)


   

22-hydroxy-1-(piperidin-1-yl)docosa-2,4-dien-1-one

22-hydroxy-1-(piperidin-1-yl)docosa-2,4-dien-1-one

C27H49NO2 (419.3763094)


   

13-{[(z,5z)-4-methoxy-1h-[2,2'-bipyrrolyliden]-5-ylidene]methyl}-2-(2-methylpropyl)-12-azabicyclo[9.2.1]tetradeca-1(13),11(14)-diene

13-{[(z,5z)-4-methoxy-1h-[2,2'-bipyrrolyliden]-5-ylidene]methyl}-2-(2-methylpropyl)-12-azabicyclo[9.2.1]tetradeca-1(13),11(14)-diene

C27H37N3O (419.2936472)


   

(1s,2r,3r,4s,5s,6s,8s,9s,10r,13r,16s,17r)-8-ethoxy-11-ethyl-6,16-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-ol

(1s,2r,3r,4s,5s,6s,8s,9s,10r,13r,16s,17r)-8-ethoxy-11-ethyl-6,16-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-ol

C25H41NO4 (419.30354260000007)


   

hexadecanoyl (2s)-2-amino-3-(4-hydroxyphenyl)propanoate

hexadecanoyl (2s)-2-amino-3-(4-hydroxyphenyl)propanoate

C25H41NO4 (419.30354260000007)


   

5-(5-hydroxyoctyl)-2-methyl-decahydroquinolin-3-yl octa-2,4-dienoate

5-(5-hydroxyoctyl)-2-methyl-decahydroquinolin-3-yl octa-2,4-dienoate

C26H45NO3 (419.339926)


   

13-({4-methoxy-1'h-[2,2'-bipyrrol]-5-ylidene}methyl)-2-(2-methylpropyl)-12-azabicyclo[9.2.1]tetradeca-1(13),11(14)-diene

13-({4-methoxy-1'h-[2,2'-bipyrrol]-5-ylidene}methyl)-2-(2-methylpropyl)-12-azabicyclo[9.2.1]tetradeca-1(13),11(14)-diene

C27H37N3O (419.2936472)


   

n-(5-ethyl-5-methyl-2-oxooxolan-3-yl)-3-hydroxyoctadeca-4,6,9-trienimidic acid

n-(5-ethyl-5-methyl-2-oxooxolan-3-yl)-3-hydroxyoctadeca-4,6,9-trienimidic acid

C25H41NO4 (419.30354260000007)


   

8-ethoxy-11-ethyl-6,16-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-ol

8-ethoxy-11-ethyl-6,16-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-ol

C25H41NO4 (419.30354260000007)


   

(1s,2s,3s,4s,5r,6r,8r,9s,10r,13r,16r,17r)-8-ethoxy-11-ethyl-6,16-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-ol

(1s,2s,3s,4s,5r,6r,8r,9s,10r,13r,16r,17r)-8-ethoxy-11-ethyl-6,16-dimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-ol

C25H41NO4 (419.30354260000007)